Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2015

View Archived Issues

AbbVie reports key events from fourth quarter 2014

Daiichi Sankyo reflects on active third quarter of fiscal 2014

FDA grants orphan drug status to Almirall product for pemphigus vulgaris

Viking Therapeutics enters into collaboration for novel THRB agonists for X-ALD

Theravance Biopharma and Mylan to develop and commercialize TD-4208 for COPD

Studies support safety, bioequivalence of new ER oxycodone microsphere formulation

Adamed patents inhibitors of p53/Mdm2 and p53/Mdm4 interactions

Matinas BioPharma acquires encochleated anti-infectives developer Aquarius BioTechnologies

BMS reports development of AAK1 inhibitors

Morinaga Milk Industry prepares anti-influenza Lactobacillus-containing compositions

Incyte patents BRD4 inhibitors

Flexion Therapeutics initiates phase III trial of FX-006 for pain in osteoarthritis of the knee

First trial results of cAd3-EBOZ Ebola vaccine candidate

AB Science discloses phase I/IIb results for masitinib as second-line treatment for gastric cancer

NicOx licenses EMEA rights to InSite's AzaSite, AzaSite Xtra and BromSite

Tenapanor achieves primary endpoint in phase IIb hyperphosphatemia trial

USAMRIID study demonstrates efficacy of Ampligen in Ebola virus rodent study

FDA lifts PPAR partial clinical hold for ETC-1002

First preclinical study underway for PharmaCyte's encapsulated Melligen cells for diabetes

Kamada reports interim data from phase I/II extension study of AAT in pediatric type 1 diabetes

Merck KGaA repatriates diabetes and thyroid brands in Russia

Evoke Pharma updates on phase III program for EVK-001 in diabetic gastroparesis

Takeda discontinues DTaP/polio vaccine

Next Science wound gel inhibits biofilm development in ear infection models

FDA grants accelerated approval for Ibrance in advanced breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...